(SD2008-188) Anticancer Agents - Novel Spirohexenolides

Technology Description

UC San Diego inventors have received a patent on a new chemical compound, isolated from a natural product that can inhibit progression through the cell cycle. The new structure's use as an anti-cancer agent is in the early stage of preclinical studies. This technology relates to novel spirohexenolides, biosynthetic methods for producing these spirohexenolides. and methods of treating cancer using the novel spirohexenolides.

This patented technology is available for commercial development within the United States (USA). Detailed description is available in the hyperlinked US Patent 8,653,283.

Related Materials

• Yu WL, Jones BD, Kang M, Hammons JC, La Clair JJ, Burkart MD. Spirohexenolide A targets human macrophage migration inhibitory factor (hMIF). J Nat Prod. 2013 May 24;76(5):817-23. - 05/24/2013
• Kang MinJin , Brian D. Jones, Alexander L. Mandel, Justin C. Hammons, Antonio G. DiPasquale, Arnold L. Rheingold, James J. La Clair and Michael D. Burkart (2009) Isolation, Structure Elucidation, and Antitumor Activity of Spirohexenolides A and B J. Org. Chem, 2009, 74, 9054-9062.

Patent Status

Other Information